Carbonic anhydrase inhibitors induce elevations in human whole-blood zinc levels.
The use of carbonic anhydrase inhibitors (CAIs) was associated with mean increases in whole-blood zinc levels of 82 micrograms/dL and 70 micrograms/dL, respectively, in a cross-sectional survey and in a prospective study of patients with glaucoma. The time course of the increase suggests that CAIs induce reticulocyte synthesis of carbonic anhydrase.
D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D003300:Copper / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D005901:Glaucoma / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008297:Male; D011446:Prospective Studies; D015032:Zinc / Q000097:blood*
D002257:Carbonic Anhydrase Inhibitors; D003300:Copper; D015032:Zinc